WSTAM
SGMO

Wilbanks Smith & Thomas Asset Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-300
Closed -$5K – 1142
2018
Q3 		$5K Buy
+300
New +$4.56K ﹤0.01% 1237

Other funds holding SGMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's SGMO Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2018, closing a stake of 300 shares — an estimated $5K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in SGMO in Q3 2018 and held it in 1 quarter. The position peaked at $5K in Q3 2018. 197 funds tracked by Wall St. Rank hold SGMO as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 300 SANGAMO THERAPEUTICS INC shares in Q4 2018, an estimated $5K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's SANGAMO THERAPEUTICS INC position peaked at $5K in Q3 2018.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.